Global Psychiatric Long-acting Injection Market Growth 2024-2030
The global Psychiatric Long-acting Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Psychiatric Long-acting Injection Industry Forecast” looks at past sales and reviews total world Psychiatric Long-acting Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Psychiatric Long-acting Injection sales for 2024 through 2030. With Psychiatric Long-acting Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psychiatric Long-acting Injection industry.
This Insight Report provides a comprehensive analysis of the global Psychiatric Long-acting Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric Long-acting Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psychiatric Long-acting Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric Long-acting Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric Long-acting Injection.
United States market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Psychiatric Long-acting Injection players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric Long-acting Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Aripiprazole Long-acting Injection
Haloperidol Long-acting Injection
Paliperidone Long-acting Injection
Risperidone Long-acting Injection
Olanzapine Long-acting Injection
Others
Segmentation by Application:
Schizophrenia
Bipolar Disorder
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Oakwood Labs
Teva
MedinCell
Janssen
Otsuka America Pharmaceutical, Inc.
Lundbeck
Eli Lilly
Alkermes
Par Pharmaceutical
AbbVie
Luye Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Psychiatric Long-acting Injection market?
What factors are driving Psychiatric Long-acting Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric Long-acting Injection market opportunities vary by end market size?
How does Psychiatric Long-acting Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.